Kelly shares her thoughts on the new OmniPod Personal Data Manager (PDM).

Update on the Odyssey

On April 1st, diaTribe traveled to Washington DC to observe the regulatory discussions on a new diabetes drug that is waiting for approval in the US (it is also awaiting...

Dr. Desmond Schatz, type 1 diabetes expert.

Here at diaTribe, we know how difficult it can be to wade through the masses of diabetes-related information sources out there. However, a new website launched in...

Two new exciting JDRF partnerships highlight the changing landscape in diabetes.

Enter our Blood Glucose Test Strip Giveaway to have a chance of winning a grand prize of one year's worth of OneTouch Ultra test strips (based on about 5 strips per day...

An old standard charges new debates: challenges to the value of A1c testing.

After an intense day of deliberations earlier this month, an FDA advisory committee delivered an overwhelmingly positive vote (20-2) in favor of the approval of Vivus’...

Kelly reflects on how three ‘small’ changes in diabetes and obesity care may have gigantic long-term effects.

Recently, data were reported from the DURATION-3 study comparing Amylin’s Byetta Once Weekly (formerly known as LAR )—the next-generation, once-weekly formulation of the...

(S)he said what?!?

If you’re a regular diaTribe reader, you probably know that we’re big fans of Continuous Glucose Monitoring (CGM)—devices that let you see your glucose levels in real-...

A racy ‘Insulin Story’ from the Big Apple.

The staff here at diaTribe has had many great things to say about the OmniPod the disposable “patch pump” from Insulet. Our editor-in-chief, Kelly Close, has been a...

Sonia Sotomayor is the first Supreme Court Justice nominee with type 1 diabetes. Jim Hirsch explains how he got involved in the White House's efforts to handle the...

Yet another breakthrough in the battle against hypoglycemia and hypoglycemia unawareness! Medtronic, using a new sensor algorithm, has developed a “low-glucose suspend...

Beyond the Basals - Part I

On April 2nd, right after the saxagliptin meeting, the FDA Advisory Committee discussed liraglutide, a once-daily injectable medication for type 2 diabetes that works in...

Where is my soapbox? I’ve got much to say and only 500 words to spare.